| CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH |
Cumberland leveraging Qureight's deep-learning AI platform for its Phase II FIGHTING FIBROSIS™ clinical trial NASHVILLE, Tenn. and CAMBRIDGE, England , May 13, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced a partnership with Qureight, a Core Imaging Laboratory developing deep-learning image analytics, to enhance the outcome and output of data from Cumberland's FIGHTING FIBROSIS™ clinical trial. |
prnewswire.com |
2025-05-13 20:05:00 |
Czytaj oryginał (ang.) |
| Cumberland Pharmaceuticals, Inc. (CPIX) Q1 2025 Earnings Call Transcript |
Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX ) Q1 2025 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Molly Aggas - Account Supervisor, Dalton Agency A.J. Kazimi - CEO Todd Anthony - VP, Organizational Development John Hamm - CFO Conference Call Participants Operator Good afternoon, and welcome to the Cumberland Pharmaceuticals First Quarter 2025 Financial Report and Company Update. |
seekingalpha.com |
2025-05-10 08:23:42 |
Czytaj oryginał (ang.) |
| Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025 |
NASHVILLE, Tenn. , May 6, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $11.7 million during the first quarter of 2025, a 38% increase over the prior year period. |
prnewswire.com |
2025-05-06 20:05:00 |
Czytaj oryginał (ang.) |
| CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE |
NASHVILLE, Tenn. , April 29, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2025 financial results and provide a Company update after the market closes on Tuesday, May 6, 2025. |
prnewswire.com |
2025-04-29 20:05:00 |
Czytaj oryginał (ang.) |
| FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference |
Ifetroban demonstrated significant 5.4% improvement in cardiac function NASHVILLE, Tenn. , March 19, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on rare diseases, today announced that results from its Phase 2 FIGHT DMD clinical trial were selected for a late-breaking presentation at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas. |
prnewswire.com |
2025-03-19 18:05:00 |
Czytaj oryginał (ang.) |
| Cumberland Pharmaceuticals Inc. (CPIX) Q4 2024 Earnings Call Transcript |
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Molly Aggas – Account Supervisor-Dalton Agency A.J. Kazimi – Chief Executive Officer Todd Anthony – Vice President-Organizational Development John Hamm – Chief Financial Officer Conference Call Participants Operator Good afternoon, and welcome to Cumberland Pharmaceuticals Fourth Quarter 2024 Financial Report and Company Update. |
seekingalpha.com |
2025-03-04 21:14:30 |
Czytaj oryginał (ang.) |
| Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth |
2024 highlights include expanded product labeling, key FDA designations and new study publications Recent developments include Phase 2 DMD Study Breakthrough Results and Vibativ China approval NASHVILLE, Tenn. , March 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $10.4 million during the fourth quarter of 2024, an 11.6% increase over the prior year period. |
prnewswire.com |
2025-03-04 18:05:00 |
Czytaj oryginał (ang.) |
| CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS |
NASHVILLE, Tenn. , Feb. 25, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its annual 2024 financial results and provide a company update after the market closes on Tuesday, March 4, 2025. |
prnewswire.com |
2025-02-25 18:05:00 |
Czytaj oryginał (ang.) |
| VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA |
Vibativ® is a life-saving antibiotic for pneumonia and serious skin infections Approval in China paves the way for launch in world's second-largest market NASHVILLE, Tenn. and SHANGHAI , Feb. 18, 2025 /PRNewswire/ -- Specialty pharmaceutical companies Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) and SciClone Pharmaceuticals (Holdings) Limited ("SciClone Pharmaceuticals" or "SciClone") today announced the NMPA (National Medical Products Administration) approval of Cumberland's Vibativ® (telavancin) injection in China. |
prnewswire.com |
2025-02-18 09:30:00 |
Czytaj oryginał (ang.) |
| Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease |
On Tuesday, Cumberland Pharmaceuticals Inc. CPIX released topline results from its Phase 2 FIGHT DMD trial. |
benzinga.com |
2025-02-04 15:31:48 |
Czytaj oryginał (ang.) |
| Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease |
NASHVILLE, Tenn. , Feb. 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced positive top-line results from its Phase 2 FIGHT DMD trial. |
prnewswire.com |
2025-02-04 09:30:00 |
Czytaj oryginał (ang.) |
| Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday? |
On Monday, the FDA approved Cumberland Pharmaceuticals Inc's CPIX supplemental New Drug Application (sNDA) for its Acetadote (N-acetylcysteine for injection) product. |
benzinga.com |
2024-12-10 14:08:21 |
Czytaj oryginał (ang.) |
| FDA APPROVES ACETADOTE® sNDA |
- New Dosing Regimen Simplifies Administration - NASHVILLE, Tenn. , Dec. 9, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced today the FDA has approved a supplemental New Drug Application (sNDA) for its Acetadote® (N-acetylcysteine for injection) product. |
prnewswire.com |
2024-12-09 18:05:00 |
Czytaj oryginał (ang.) |
| Cumberland Pharmaceuticals Inc. (CPIX) Q3 2024 Earnings Call Transcript |
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Molly Aggas - Investor Relations, Dalton Agency A.J. Kazimi - Chief Executive Officer Todd Anthony - Vice President, Organizational Development John Hamm - Chief Financial Officer Conference Call Participants Operator Good afternoon. |
seekingalpha.com |
2024-11-09 15:17:44 |
Czytaj oryginał (ang.) |
| Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update |
– New Real World Study of 150,000 Patients Favors Caldolor over ketorolac – – DMD Program Receives FDA Orphan Drug & Rare Pediatric Disease Designations – NASHVILLE, Tenn. , Nov. 7, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced that its portfolio of FDA-approved brands delivered combined revenues of $9.1 million during the third quarter of 2024. |
prnewswire.com |
2024-11-07 18:05:00 |
Czytaj oryginał (ang.) |
| CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY |
NASHVILLE, Tenn. , Nov. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that the United States (U.S.) Food and Drug Administration (FDA) granted Orphan Drug Designation and Rare Pediatric Disease Designation to Ifetroban for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). |
prnewswire.com |
2024-11-06 19:21:00 |
Czytaj oryginał (ang.) |
| New Study Compares Caldolor® (ibuprofen injection) to ketorolac |
– Real World Study Compared Over 150,000 Adult & Pediatric Patients – – Caldolor Associated with Fewer Adverse Drug Reactions – – Caldolor also Improved Healthcare Utilization – NASHVILLE, Tenn. , Nov. 5, 2024 /PRNewswire/ -- Specialty pharmaceutical company Cumberland Pharmaceuticals (Nasdaq: CPIX) today announced the publication of new real-world outcomes research demonstrating the safety and healthcare resource advantages of its Caldolor (ibuprofen) injection over ketorolac in both adult and pediatric populations. |
prnewswire.com |
2024-11-05 18:05:00 |
Czytaj oryginał (ang.) |
| CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS |
NASHVILLE, Tenn. , Oct. 31, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2024 financial results and provide a company update after the market closes on Thursday, Nov. 7, 2024. |
prnewswire.com |
2024-10-31 18:05:00 |
Czytaj oryginał (ang.) |
| Cumberland Pharmaceuticals Inc. (CPIX) Q2 2024 Earnings Call Transcript |
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX ) Q2 2024 Results Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Molly Aggas - Investor Relations, Dalton Agency A.J. Kazimi - Chief Executive Officer Todd Anthony - Vice President, Organizational Development John Hamm - Chief Financial Officer Conference Call Participants Operator Good afternoon. |
seekingalpha.com |
2024-08-11 16:47:08 |
Czytaj oryginał (ang.) |
| Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024 |
NASHVILLE, Tenn. , Aug. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced significantly improved financial results and a favorable overall company performance for the second quarter of 2024. |
prnewswire.com |
2024-08-06 20:05:00 |
Czytaj oryginał (ang.) |
| CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2024 FINANCIAL RESULTS |
NASHVILLE, Tenn. , July 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2024 financial results and provide a company update after the market closes on Tuesday, Aug. 6, 2024. |
prnewswire.com |
2024-07-30 20:05:00 |
Czytaj oryginał (ang.) |
| Cumberland Pharmaceuticals Inc. (CPIX) Q1 2024 Earnings Call Transcript |
Start Time: 15:30 January 1, 0000 3:59 PM ET Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX ) Q1 2024 Earnings Conference Call May 07, 2024, 15:30 PM ET Company Participants A.J. Kazimi - CEO Todd Anthony - VP, Organizational Development John Hamm - CFO Molly Aggas - Account Supervisor, Dalton Agency Conference Call Participants Operator Good afternoon, and welcome to Cumberland Pharmaceuticals First Quarter 2024 Financial Report and Company Update. |
seekingalpha.com |
2024-05-12 03:51:04 |
Czytaj oryginał (ang.) |
| Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update |
NASHVILLE, TENN., May 7, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced that its product portfolio of FDA-approved brands delivered combined revenues of $8.5 million during the first quarter of 2024. |
prnewswire.com |
2024-05-07 20:05:00 |
Czytaj oryginał (ang.) |
| CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS |
NASHVILLE, Tenn. , April 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024 financial results and provide a company update after the market closes on Tuesday, May 7, 2024. |
prnewswire.com |
2024-04-30 20:05:00 |
Czytaj oryginał (ang.) |
| NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS |
Growing data shows intravenous ibuprofen is safe and effective for the treatment of pain and fever in adults, children and infants NASHVILLE, Tenn. , April 2, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced the release of a Special Report evaluating the growing amount of current data supporting the use of its Caldolor® product (intravenous ibuprofen, or IVIB) as a standard of care for the treatment of pain and fever in adults, children and infants. |
prnewswire.com |
2024-04-02 20:05:00 |
Czytaj oryginał (ang.) |
| Cumberland Pharmaceuticals Inc. (CPIX) Q4 2023 Earnings Call Transcript |
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX ) Q4 2023 Earnings Conference Call March 5, 2024 4:30 PM ET Company Participants Molly Aggas - Account Supervisor, Dalton Agency A. J. Kazimi - Chairman and Chief Executive Officer Todd Anthony - Vice President, Organizational Development John Hamm - Chief Financial Officer Conference Call Participants Operator Good afternoon, and welcome to Cumberland Pharmaceuticals 2023 Financial Report and Company Update. |
seekingalpha.com |
2024-03-06 00:06:02 |
Czytaj oryginał (ang.) |
| Cumberland Pharmaceuticals Reports Annual 2023 Financial Results |
2023 highlights include expanded FDA approval and new study publications NASHVILLE, Tenn. , March 5, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined revenues of $40 million in 2023 and provided $6 million in cash generated from operations. |
prnewswire.com |
2024-03-05 18:05:00 |
Czytaj oryginał (ang.) |
| CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS |
NASHVILLE, Tenn. , Feb. 27, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2023 financial results and provide a company update after the market closes on Tuesday, March 5, 2024. |
prnewswire.com |
2024-02-27 18:05:00 |
Czytaj oryginał (ang.) |
| Cumberland Pharmaceuticals Inc. (CPIX) Q3 2023 Earnings Call Transcript |
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Molly Aggas - Account Supervisor, Dalton Agency A. J. Kazimi - Chairman and Chief Executive Officer Todd Anthony - Vice President, Organizational Development John Hamm - Chief Financial Officer Conference Call Participants Operator Good afternoon, and welcome to Cumberland Pharmaceuticals Third Quarter 2023 Company Update and Financial Report. |
seekingalpha.com |
2023-11-11 10:17:06 |
Czytaj oryginał (ang.) |
| Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results |
NASHVILLE, Tenn. , Nov. 7, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined revenues of $10.1 million during the third quarter of 2023 and $30.2 million year to date. |
prnewswire.com |
2023-11-07 18:05:00 |
Czytaj oryginał (ang.) |
| CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS |
NASHVILLE, Tenn., Oct. 31, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the third quarter 2023 financial results and provide a company update after the market closes on Tuesday, Nov. 7, 2023. |
prnewswire.com |
2023-10-31 18:05:00 |
Czytaj oryginał (ang.) |